Source link : https://www.newshealth.biz/health-news/tolebrutinib-slows-disability-in-non-relapsing-secondary-progressive-ms/
Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton’s tyrosine kinase (BTK) inhibitor met the study’s primary endpoint of delaying time to onset of 6-month confirmed disability progression (CDP), reported Robert Fox, MD, of the Mellen Center for Multiple Sclerosis at the […]
Author : News Health
Publish date : 2024-09-20 14:47:47
Copyright for syndicated content belongs to the linked Source.
in Health